Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

481 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors.
Mita AC, Takimoto CH, Mita M, Tolcher A, Sankhala K, Sarantopoulos J, Valdivieso M, Wood L, Rasmussen E, Sun YN, Zhong ZD, Bass MB, Le N, LoRusso P. Mita AC, et al. Among authors: sun yn. Clin Cancer Res. 2010 Jun 1;16(11):3044-56. doi: 10.1158/1078-0432.CCR-09-3368. Epub 2010 May 25. Clin Cancer Res. 2010. PMID: 20501621 Clinical Trial.
Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors.
Diamond JR, Wu B, Agarwal N, Bowles DW, Lam ET, Werner TL, Rasmussen E, Gamelin E, Soto F, Friberg G, Sun YN, Sharma S. Diamond JR, et al. Among authors: sun yn. Invest New Drugs. 2015 Jun;33(3):691-9. doi: 10.1007/s10637-015-0236-4. Epub 2015 Apr 21. Invest New Drugs. 2015. PMID: 25895965 Clinical Trial.
Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors.
Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, Rasmussen E, Sun YN, Zhong D, Hwang YC, Evelhoch JL, Oliner JD, Le N, Rosen LS. Herbst RS, et al. Among authors: sun yn. J Clin Oncol. 2009 Jul 20;27(21):3557-65. doi: 10.1200/JCO.2008.19.6683. Epub 2009 Jun 22. J Clin Oncol. 2009. PMID: 19546406 Clinical Trial.
AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study.
Rini B, Szczylik C, Tannir NM, Koralewski P, Tomczak P, Deptala A, Dirix LY, Fishman M, Ramlau R, Ravaud A, Rogowski W, Kracht K, Sun YN, Bass MB, Puhlmann M, Escudier B. Rini B, et al. Among authors: sun yn. Cancer. 2012 Dec 15;118(24):6152-61. doi: 10.1002/cncr.27632. Epub 2012 Jun 12. Cancer. 2012. PMID: 22692704 Free PMC article. Clinical Trial.
Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection.
Lu JF, Rasmussen E, Karlan BY, Vergote IB, Navale L, Kuchimanchi M, Melara R, Stepan DE, Weinreich DM, Sun YN. Lu JF, et al. Among authors: sun yn. Cancer Chemother Pharmacol. 2012 May;69(5):1135-44. doi: 10.1007/s00280-011-1787-5. Epub 2012 Jan 1. Cancer Chemother Pharmacol. 2012. PMID: 22210018 Free PMC article. Clinical Trial.
Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer.
Blumenschein GR Jr, Reckamp K, Stephenson GJ, O'Rourke T, Gladish G, McGreivy J, Sun YN, Ye Y, Parson M, Sandler A. Blumenschein GR Jr, et al. Among authors: sun yn. Clin Cancer Res. 2010 Jan 1;16(1):279-90. doi: 10.1158/1078-0432.CCR-09-1675. Epub 2009 Dec 22. Clin Cancer Res. 2010. PMID: 20028752 Clinical Trial.
Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumors.
Lorusso P, Heath EI, McGreivy J, Sun YN, Melara R, Yan L, Malburg L, Ingram M, Wiezorek J, Chen L, Pilat MJ. Lorusso P, et al. Among authors: sun yn. Invest New Drugs. 2008 Oct;26(5):455-62. doi: 10.1007/s10637-008-9144-1. Epub 2008 Jun 24. Invest New Drugs. 2008. PMID: 18574557 Clinical Trial.
481 results